nanotech investing Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering 06 July
nanotech investing Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom 29 June
nanotech investing Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes 26 June
